Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e48dbfe2-f2e1-4146-ac45-949863ed90f4
Date 12/22/2014
Company Name ImmusanT
Mailing Address One Kendall Square Cambridge, MA 02139 USA
Company Description ImmusanT is an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
Proceeds Purposes The proceeds will fund the Phase 2 clinical development of Nexvax2 to demonstrate proof-of-concept as well as continued development of ImmusanT’s diagnostics.